REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
The stigma placed on mental health makes many men believe showing signs of vulnerability could be considered weak. Men experience immense amounts of internalized stigma from societal expectations, causing symptoms such as isolation, depression, anxiety, and resistance to treatment.
Platelets play one of major roles in the hemostatic process. When platelets come across the injured endothelium cells, they change shape, release granules and ultimately become ‘sticky’. Platelets express certain receptors, some of which are used for the adhesion of platelets to collagen. When platelets are activated, they express glycoprotein receptors that interact with other platelets, producing aggregation and adhesion. Platelets release cytoplasmic granules such as adenosine diphosphate (ADP), serotonin and thromboxane A2. Adenosine diphosphate (ADP) attracts more platelets to the affected area, serotonin is a vasoconstrictor and thromboxane A2 assists in platelet aggregation, vasoconstriction and degranulation. As more chemicals are released more platelets stick and release their chemicals; creating a platelet plug and continuing the process in a positive feedback loop. 5-Hydroxykynurenamine, a metabolite of serotonin, has been found to inhibit serotonin-induced platelet aggregation. This indicates that it may regulate platelet activity during hemostasis and thrombogenesis by modulating the effects of serotonin on blood clot formation. Platelets alone are responsible for stopping the bleeding of unnoticed wear and tear of our skin on a daily basis. This is referred to as primary hemostasis.
== Early life == Steve Austin was born Steven James Anderson on December 18, 1964, in Austin, Texas. After his parents divorced, his mother moved the family to Victoria, Texas, raising Austin and his two brothers, Scott and Kevin, as a single parent. She later married Ken Williams, who adopted the children; Austin's name was legally changed to Steven James Williams. The family eventually settled in Edna, Texas. Austin also has a third brother, Jeff, and a sister, Jennifer. He attended Edna High School where he was a running back for the schools football team all 4 years. Following his graduation he then attended Wharton County Junior College for one year where he played linebacker. After a successful season with the team he was offered a full scholarship and transferred to the University of North Texas. He continued playing as a linebacker but switched to defensive end after a knee injury. Austin's father also played football at Rice University. Austin later reflected on his football career stating "It was a fun experience," "I had dreams of being a pro football player but just couldn't quite make the grade by a long-shot on that. I was a good player at the local or regional level. Beyond that, those guys had too much talent." He ultimately dropped out of college just a few credits short of graduating. Austin developed an early interest in professional wrestling, regularly watching Houston Wrestling promoted by Paul Boesch. While in college, he lived near the Dallas Sportatorium, where World Class Championship Wrestling (WCCW) held events.
After a trial season with the Joe Ruttman-driven and Larry McClure-owned Chevrolet in 1985, Folgers expanded its sponsorships. In 2006, the advertising agency Saatchi & Saatchi created a viral advertisement, popularly known as "Happy Mornings", in which a large group of cheerful singers and dancers appear at sunrise as the sun itself to wake people up. In 2009, Saatchi & Saatchi created a holiday ad, "Coming Home", wherein a man reunites with his teenage sister at their parents' home after volunteering in West Africa. The ad quickly went viral, and has been criticized for perceived sexual tensions between the siblings. In 2014, the brand celebrated the 30th anniversary of the famous jingle.
is the distance traveled by the liquid. More extensive models account for paper tortuosity, pore radius, and paper deformation. Once the medium is fully wetted, subsequent flow is laminar and follows Darcy's law. The average velocity of fluid flow is generalized as,
Sources: en.wikipedia.org
== Evolution == The opioid receptor (OR) family originated from two duplication events of a single ancestral opioid receptor early in vertebrate evolution. Phylogenetic analysis demonstrates that the family of opioid receptors was already present at the origin of jawed vertebrates over 450 million years ago. In humans, this paralogon resulting from a double tetraploidization event resulted in the receptor genes being located on chromosomes 1, 6, 8, and 20. Tetraploidization events often result in the loss of one or more of the duplicated genes, but in this case, nearly all species retain all four opioid receptors, indicating biological significance of these systems. Stefano traced the co-evolution of OR and the immune system underlying the fact that these receptors helped earlier animals to survive pain and inflammation shock in aggressive environments. The receptor families delta, kappa, and mu demonstrate 55–58% identity to one another, and a 48–49% homology to the nociceptin receptor. Taken together, this indicates that the NOP receptor gene, OPRL1, has equal evolutionary origin, but a higher mutation rate, than the other receptor genes. Although opioid receptor families share many similarities, their structural differences lead to functional difference. Thus, mu-opioid receptors induce relaxation, trust, satisfaction, and analgesia. This system may also help mediate stable, emotionally committed relationships. Experiments with juvenile guinea pigs showed that social attachment is mediated by the opioid system.
== Use as a biomarker == Dinosterol is used as a biomarker for organic matter derived from dinoflagellates in sediments and seawater. Biomarkers are organic compounds that are indicative of former life in sediments, seawater and oil. The presence of the saturated hydrocarbon counterpart, dinosterane, is used as evidence that some of the organic matter present in ancient sediments may have been derived from dinoflagellates.
Professor Richard Hilary Templer. Lately Director of Innovation, Grantham Institute, Imperial College London. For services to Climate Innovation. Dr. Gillian Romaine Tett. Editorial Board, Financial Times. For services to Economic Journalism. Usha Ladwa-Thomas. Race Adviser, Welsh Government. For services to Black, Asian and Minority Ethnic Communities. Margaret Ann Throup, MP. Member of Parliament for Erewash. For Political and Public Service. Jane Elizabeth Toogood. Co-Chair, Hydrogen Delivery Council. For services to the Low Carbon Hydrogen Sector. Sara Louise Tough. Executive Director, Children's Services, Norfolk County Council. For services to Education and Children's Social Care. John Henry Trayner. Lately Managing Director, Go-Ahead London. For services to Transport, to Skills and to Education in London. Marcus Edward Trescothick. Mental Health Ambassador, Professional Cricketers' Association. For services to Mental Ill Health. Professor Joyce Ann Tyldesley. Professor of Egyptology, University of Manchester. For services to Egyptology and Heritage. Nicola Madeline van der Drift. Chief Executive, International Bomber Command Centre. For services to Heritage. Louise van der Straeten. Senior Lawyer, Serious Fraud Office. For services to the Administration of Justice. Vinaichandra Guduguntla Venkatesham. Chief Executive Officer, Arsenal Football Club. For services to Sport. Ewan Andrew Venters. Chief Executive, Hauser & Wirth and Chair, GREAT Private Sector Council. For services to International Trade. Robert Iain Wainwright. Founder, Doddie Aid.
=== Chemical synthesis === Digital Microfluidics (DMF) allows for precise manipulation and coordination in small-scale chemical synthesis reactions due to its ability to control micro scale volumes of liquid reagents, allowing for overall less reagent use and waste. This technology can be used in the synthesis compounds such as peptidomimetics and PET tracers. PET tracers require nanogram quantities and as such, DMF allows for automated and rapid synthesis of tracers with 90-95% efficiency compared to conventional macro-scale techniques. Organic reagents are not commonly used in DMF because they tend to wet the DMF device and cause flooding; however synthesis of organic reagents can be achieved through DMF techniques by carrying the organic reagents through an ionic liquid droplet, thus preventing the organic reagent from flooding the DMF device. Droplets are combined together by inducing opposite charges thus attracting them to each other. This allows for automated mixing of droplets. Mixing of droplets are also used to deposit MOF crystals for printing by delivering reagents into wells and evaporating the solutions for crystal deposition. This method of MOF crystal deposition is relatively cheap and does not require extensive robotic equipment. Chemical synthesis using digital microfluidics (DMF) has been applied to many noteworthy biological reactions. These include polymerase chain reaction (PCR), as well as the formation of DNA and peptides.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.